Epic Update Jubilant Life Sciences
Share price of Jubilant Life Sciences added 5.7 percent intraday Tuesday on USFDA approval for Olmesartan Medoxomil tablets.
The company has received Abbreviated New Drug Application (ANDA) final approval for Olmesartan Medoxomil tablets, 5mg, 20 mg and 40 mg, the generic version of Benicar of Daiichi Sankyo, which is used for treatment of hypertension.
This is second approval that company has received from the USFDA during the current financial year.
As on December 2016, the company had a total of 73 ANDAs for oral solids filed in the US, out of which 49 have been approved.
Jubilant Life Sciences was quoting at Rs 829.70, up Rs 39.50, or 5 percent on the BSE.
For more information & more Stocks to buy today
Share price of Jubilant Life Sciences added 5.7 percent intraday Tuesday on USFDA approval for Olmesartan Medoxomil tablets.
The company has received Abbreviated New Drug Application (ANDA) final approval for Olmesartan Medoxomil tablets, 5mg, 20 mg and 40 mg, the generic version of Benicar of Daiichi Sankyo, which is used for treatment of hypertension.
This is second approval that company has received from the USFDA during the current financial year.
As on December 2016, the company had a total of 73 ANDAs for oral solids filed in the US, out of which 49 have been approved.
Jubilant Life Sciences was quoting at Rs 829.70, up Rs 39.50, or 5 percent on the BSE.
For more information & more Stocks to buy today
Call us ✆ – 0731-6642300 or
Visit http://www.epicresearch.co
Connect with our social media sites
Follow @Epic_Research
Visit http://www.epicresearch.co
Connect with our social media sites
Follow @Epic_Research
Sign up here with your email